JP2021530498A5 - - Google Patents

Info

Publication number
JP2021530498A5
JP2021530498A5 JP2021500858A JP2021500858A JP2021530498A5 JP 2021530498 A5 JP2021530498 A5 JP 2021530498A5 JP 2021500858 A JP2021500858 A JP 2021500858A JP 2021500858 A JP2021500858 A JP 2021500858A JP 2021530498 A5 JP2021530498 A5 JP 2021530498A5
Authority
JP
Japan
Prior art keywords
domain
igg1
domain monomer
monomer
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041468 external-priority patent/WO2020014526A2/en
Publication of JP2021530498A publication Critical patent/JP2021530498A/ja
Publication of JP2021530498A5 publication Critical patent/JP2021530498A5/ja
Withdrawn legal-status Critical Current

Links

JP2021500858A 2018-07-11 2019-07-11 CD38を標的とする改変Fc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021530498A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696759P 2018-07-11 2018-07-11
US62/696,759 2018-07-11
US201862733036P 2018-09-18 2018-09-18
US62/733,036 2018-09-18
US201862744067P 2018-10-10 2018-10-10
US62/744,067 2018-10-10
PCT/US2019/041468 WO2020014526A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Publications (2)

Publication Number Publication Date
JP2021530498A JP2021530498A (ja) 2021-11-11
JP2021530498A5 true JP2021530498A5 (cg-RX-API-DMAC7.html) 2022-07-15

Family

ID=69141927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500858A Withdrawn JP2021530498A (ja) 2018-07-11 2019-07-11 CD38を標的とする改変Fc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20210269546A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820516A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530498A (cg-RX-API-DMAC7.html)
KR (1) KR20210044218A (cg-RX-API-DMAC7.html)
CN (1) CN113194990A (cg-RX-API-DMAC7.html)
AU (1) AU2019299973A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000416A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106142A1 (cg-RX-API-DMAC7.html)
IL (1) IL280046A (cg-RX-API-DMAC7.html)
MX (1) MX2021000307A (cg-RX-API-DMAC7.html)
WO (1) WO2020014526A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN115873127B (zh) * 2021-11-26 2026-04-10 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
CN118613504A (zh) * 2021-12-17 2024-09-06 摩德斯医疗股份有限公司 含有tnfsf配体的细胞外结构域的抗原结合多肽复合物
WO2025229160A1 (en) * 2024-05-01 2025-11-06 Commit Biologics Aps Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
MX387324B (es) * 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
PE20171094A1 (es) * 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
BR112019009495A2 (pt) * 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes

Similar Documents

Publication Publication Date Title
JP2021532085A5 (cg-RX-API-DMAC7.html)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2020514301A5 (cg-RX-API-DMAC7.html)
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
JP2020508655A5 (cg-RX-API-DMAC7.html)
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
JP2022519118A5 (cg-RX-API-DMAC7.html)
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
JP2021531268A5 (cg-RX-API-DMAC7.html)
RU2007139953A (ru) Антитела к ccr5 и их применение
DE602004021702D1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2021530989A5 (cg-RX-API-DMAC7.html)
DE50210328D1 (de) Bispezifisches anti-cd28 antikörper-molekül
RU2018129878A (ru) Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
DK1697421T3 (da) Bispecifikke antistoffer
RU2602878C3 (ru) Конъюгаты "производное калихеамицина-носитель"
RU2016138347A (ru) Трифункциональная антигенсвязывающая молекула
NZ588713A (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
ATE423140T1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
WO2007048037A3 (en) METHODS FOR GENERATING MONOVALENT IgG
JP2021531756A5 (cg-RX-API-DMAC7.html)
MX2025010747A (es) Union de anticuerpos biespecificos al dominio similar a la proteasa del receptor transferrina humano htfr1